Sedana Medical AB (publ) (SEDANA) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Hello everyone, and welcome to today's presentation with Sedona Medical. With us presenting today, we have the CEO, Johannes Dahl, CFO, Johan Spets, and CMO, Peter Sacchi. We'll do a Q&A after the presentation, and if you're calling in and would like us to ask a question, please press star nine to raise your hand, and star six to unmute yourself when you get the word. You can also type in the question just in the form to the right. And with that said, please go ahead with your presentation. Thank you for the introduction and welcome to our Q2 report presentation. I know that some of you are taking a break from your summer break to be with us, which we appreciate a lot. So thanks a lot for taking the time with us today. Let's start on page three, please. The first half of 2025 is over. It was a very successful period for Sedana Medical. We have had new all-time highs in sales. Q1 was the best Q1 we've ever had and Q2 was the best Q2 we've ever had. We're looking at a positive year-to-date EBITDA in our ex-US business and are on track to achieve our financial target. And in the US, we've received positive clinical trial results. We got an early access program approved and have FDA fast-track designation. So overall, many reasons to be proud of the progress we have made during these two quarters. Let's dive into it. Q2 sales landed just under 50 million SEC, a year-over-year growth of 27%, of which 21% were organic growth and 6% came from contract manufacturing revenue stemming from our newly acquired manufacturing plant in Malaysia. And what really stands out this quarter is that we had excellent performance in our main market, Germany, with 19% growth, which I'm very happy about because, as you know, We've been working hard to reignite growth after having a slightly l...